Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Abemaciclib for advanced breast cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 1119

Dr Angelo Di Leo - Hospital of Prato, Tuscany, Italy

Dr Di Leo speaks with ecancer at the ESMO 2017 Congress in Madrid about the MONARCH 3 trial investigating the use of abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer. 

Watch Dr Di Leo present the data in a press conference for more, and read our news coverage here.

ecancer also hosted a round table discussion of CDK4/6 inhibitors at ESMO, which you can watch here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence